European CHMP recommends approval of licence extension of methotrexate (Nordimet)
The licence extension is for induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.
Source:
European Medicines Agency